Cost-Effectiveness of Atypical Antipsychotics for the Treatment of Relapse Prevention for Bipolar Disorder: The Russian Perspective

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.1585
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Atypical Antipsychotics for the Treatment of Disruptive Behavior

Pediatric Annals
Child HealthPediatricsPerinatology
2013English

Psychosocial Interventions for the Prevention of Relapse in Bipolar Disorder: Systematic Review of Controlled Trials

British Journal of Psychiatry
MedicinePsychiatryMental Health
2008English

Antipsychotics for the Prevention and Treatment of Delirium

2019English

Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States

Cost Effectiveness and Resource Allocation
Health Policy
2009English

Both Typical and Atypical Long-Acting Injectable Antipsychotics in Bipolar Disorder: A Retrospective Chart Review

Journal of Mood Disorders
2014English

Cost-Effectiveness of Antiretroviral Therapy for Prevention

Current HIV Research
VirologyInfectious Diseases
2011English

Long-Acting Injectable Antipsychotics as Maintenance Treatments for Bipolar Disorder-A Critical Review of the Evidence

Bipolar Disorders
PsychiatryBiological PsychiatryMental Health
2018English

Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Metabolic Effects of Treatment With Atypical Antipsychotics

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy